Biofocus DPI and TET Systems Holding have entered into an agreement to apply TET's inducible gene technology in high-throughput screening campaigns performed for Biofocus customers.
Biofocus DPI will offer TET technology as part of its drug discovery screening service.
Through this technology, the activity of individual genes can be controlled quantitatively and reversibly in cellular assays.
This approach is particularly useful in cases where the target is not well tolerated in the cells, since the protein will not be expressed until required for screening.
'Using this technology, we will be able to perform more efficient, extensive compound screening on problematic targets,' said Dr Kate Hilyard, vice-president biological sciences, Biofocus DPI.
